Dimerization Protein 2 (JDP2), a downstream target of PU.1 which represses acetylation of core histones in vitro and in vivo, was significantly suppressed [5] . JDP2 mediates broader effects on regulation of lineage-differentiation programs [6, 7] and has also been found downregulated in AML patients [6] but its role in MDS has not been explored. In this study, we measured the gene expression of PU.1 and JDP2 in total bone marrow and selected CD34+ cells from 12 newly diagnosed MDS patients stratified according to IPSS-R score (6-low, 3-intermediate, 3-high risk), 2 AML patient and 10 normal controls. Results obtained were also compared with a larger cohort of patients from Bloodspot data [8] .
Both PU.1 and JDP2 were down regulated in our MDS patients compared to normal controls. In addition, we found an inverse correlation between PU.1/JDP2 expression and disease status, with expression of these genes declining with more aggressive disease per IPSS-R classification (F = 2.95, p < .04 and F = 3.5, p < .03 respectively), and with lowest levels in AML (Fig. 1a) . To extend the results, we examined PU.1 and JDP2 expression data in MDS vs normal samples in the Bloodspot expression database, and again, PU.1/JDP2 were significantly downregulated in MDS vs normal controls (p < 0.01; p < 0.05, respectively) (Fig. 1b) . A positive correlation of PU.1 and JDP2 expression (R = 0.9333, s = 0.0004) was also consistent with a regulatory link between these two genes. To confirm that JDP2 suppression is a direct result of reduced PU.1, we initially performed PU.1-knockdown in K562 cells stably expressing PU.1 short interfering RNAs versus control cells (Fig. 1c) and successively re-expressed PU.1 by transfection. Interestingly, these analyses reveal only a partial reduction in JDP2 expression when analysed by RT-PCR and Western blot ( Fig. 1d ) and when PU.1 is fully reexpressed, this does not coincide with JDP2 re-gain ( Fig. 1e) , suggesting a more complex regulatory mechanism. PU.1 and JDP2 expression correlate and are concurrently reduced with the extent of differentiation arrest and aggression/prognosis in MDS/AML. Furthermore, in patients achieving a clinically significant response to Azacitidine, we demonstrated a significant upregulation in PU.1 and JDP2 expression compared with non-responders (Fig. 1f) . This suggests that PU.1/JDP2 could be prognostic and potentially a prediction biomarkers for 5-azacytidine and/or decitabine therapy in MDS. Further studies on a larger cohort of patient are undergoing to establish the impact of PU.1/JDP2 expression in MDS evolution.
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